PCSK9-neutralizing monoclonal antibodies

Intervention

1 finding

What did studies of PCSK9-neutralizing monoclonal antibodies find?

1

Studies of PCSK9-neutralizing monoclonal antibodies measured one outcome, atherosclerotic cardiovascular disease.

Atherosclerotic cardiovascular disease

downin reviews1

1 study
  1. PCSK9-neutralizing monoclonal antibodies decrease atherosclerotic cardiovascular disease.

    “Monoclonal antibodies that neutralize circulating PCSK9 have demonstrated the utility of PCSK9 inhibition for reducing LDL-C and ASCVD.”

    Review

    In-vivo CRISPR/Base-Editing "One-Shot" Therapies Targeting PCSK9

    Current atherosclerosis reports

More on Atherosclerotic cardiovascular disease